Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment

Inclusion Criteria:

• Patients ≥ 18 years old and diagnosed with metastatic RCC who, in the investigator'sopinion, are candidates for starting first-line treatment with a tyrosine kinaseinhibitor according to routine clinical practice.
• Patients who have no contraindications to the treatment.
• Baseline ECOG ≤ 2.
• Patients who are able to give informed consent on their own without the need for alegal representative.
• Committed patients who are able to complete the quality of life questionnaires andpatient diary on their own without the need for a legal representative.

Exclusion Criteria:

• Patients who are not candidates for first-line treatment with a tyrosine kinaseinhibitor.
• Patients who are receiving the treatment as second-line or subsequent therapy.
• Untreated hypothyroidism.
• Untreated severe anaemia.
• Pregnancy or breast-feeding.
• Myocardial infarction or cerebrovascular accidents (CVA) within the last 6 months.
• Severe hepatic impairment.
• Concomitant use of potent inhibitors or inducers that interact with hepatic cytochromeCYP3A4.